Friday, May 5, 2017

BRIEF-Teva and Active Biotech announce CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint

* Teva and Active Biotech announce CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint

by reutersCOMPANYNEWS via Endless Supplies .Biz - News
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)